Peptide Lab HQ Research Guide
Cerebrolysin
A research-focused compound profile covering Cerebrolysin identity, porcine-derived neuropeptide complex research, neurorecovery models, stroke and traumatic brain injury research context, solution-strength reference, handling reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Cerebrolysin |
|---|---|
| Compound Type | Porcine brain-derived neuropeptide preparation / peptide-amino acid complex |
| Source Material | Derived from purified porcine brain proteins through standardized enzymatic breakdown; verify supplier documentation. |
| Single Peptide? | No. Cerebrolysin is a complex mixture of low-molecular-weight peptides and free amino acids, not a single defined peptide sequence. |
| Standard Product Form | Ready-to-use aqueous solution for injection; not a lyophilized peptide powder in standard pharmaceutical form. |
| Official Strength Reference | 1 mL contains 215.2 mg Cerebrolysin concentrate in aqueous solution. |
| Excipients | Sodium hydroxide and water for injection, according to official prescribing information. |
| Molecular Formula | Not applicable as a single formula because Cerebrolysin is a complex peptide/amino-acid preparation. |
| Molecular Weight | Not applicable as a single molecular weight because Cerebrolysin is a mixture. |
| Research Category | Neurorecovery, neuroprotection, stroke research, traumatic brain injury research, dementia research, neurotrophic signaling, synaptic plasticity, and cognitive-function research |
| Regulatory Context | Prescription medication in some international markets; not FDA-approved for sale or distribution in the United States. |
| Appearance | Clear amber aqueous solution in standard commercial presentation; verify against supplier documentation. |
| Use | For educational and laboratory research-reference purposes only. |
Research Applications
Key Research Applications
Cerebrolysin is commonly discussed in controlled research models involving neurorecovery, neuroprotection, stroke recovery context, traumatic brain injury models, dementia-related cognitive research, neurotrophic signaling, synaptic plasticity, and neuronal survival pathways.
Neurorecovery Research
Cerebrolysin is commonly studied in neurorecovery contexts involving neuronal repair pathways, functional recovery markers, and post-injury neurological outcome measures.
Stroke Research Context
Clinical and preclinical research has evaluated Cerebrolysin in ischemic stroke recovery models, often alongside rehabilitation or standard-care study designs.
Traumatic Brain Injury Models
Cerebrolysin is commonly discussed in traumatic brain injury research involving neuronal survival, neuroinflammation, cognitive outcomes, and functional recovery markers.
Dementia / Cognitive Research
Research contexts include Alzheimer’s-type dementia, vascular dementia, cognitive impairment, and neurodegenerative pathway observations.
Neurotrophic Signaling
Cerebrolysin is frequently framed around neurotrophic-like activity, neuronal metabolism, synaptic plasticity, and cellular repair signaling.
Complex Peptide Preparation Research
Because Cerebrolysin is a peptide/amino-acid complex rather than a single compound, research interpretation depends heavily on product identity, source, standardization, and quality documentation.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on study design, patient population or model type, route, timing, product source, storage conditions, and laboratory handling.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 20 mg Cerebrolysin |
|---|---|
| Primary Solution Volume | 1.0 mL bacteriostatic water |
| Primary Concentration | 20 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 20 mg/mL, 1 unit equals 0.2 mg / 200 mcg Cerebrolysin reference material. |
| Mixture Reference | Cerebrolysin is treated here as a total reference-material amount. Component-level peptide distribution is supplier- and batch-dependent. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light, unless supplier documentation specifies otherwise. |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution may appear clear to slightly hazy depending on supplier format, peptide-mixture composition, and concentration. Do not shake!
- Because this is a concentrated 20 mg/mL preparation and Cerebrolysin is a mixture-based reference material, verify complete dissolution and compatibility before recording final preparation details.
- Label with compound name, total reference-material amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light, unless supplier documentation specifies otherwise.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Cerebrolysin, peptide / peptidergic mixture reference material | Cerebrolysin is commonly discussed as a mixture of low-molecular-weight peptides and neurotrophic-like fragments rather than as a single defined peptide sequence. |
| Neurotrophic-Marker Research | NGF / BDNF / neurotrophin-system context | Cerebrolysin-related research is commonly discussed in relation to neurotrophin systems, NGF markers, BDNF markers, Trk receptor markers, and neuroplasticity-related endpoints. |
| Neuroprotection Research Context | Model-dependent concentration and endpoint tracking | Commonly discussed in neuroprotection, neuronal survival, synaptic-marker, oxidative-stress-marker, inflammatory-marker, and cellular-stress-response research contexts. |
| Cognition / Aging Research Context | Preclinical and clinical-study context | Cerebrolysin has been discussed in cognitive-marker, aging, memory, learning, neurodegenerative-model, and dementia-related research contexts. These clinical-study references are not research-chemical dosing standards. |
| Injury / Repair Model Context | Spinal-cord injury, traumatic brain injury, and stroke-model discussion | Research discussions commonly include spinal-cord injury, traumatic brain injury, ischemia-model, tissue-repair, synaptic-protection, and functional-recovery marker observations. |
| Mixture-Based Calculation Context | Total reference-material amount | The tables below calculate total Cerebrolysin reference-material amount only. They do not estimate individual peptide-fragment amounts, neurotrophic-factor equivalents, or potency units. |
| Public Protocol-Style Reference | Mass-based reference examples | Public protocol-style references may describe Cerebrolysin using mass-based, volume-based, or product-specific examples depending on format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, preclinical references, product-format references, or public protocol-style references should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 20 mg | 1.0 mL | 20 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 20 mg/mL | U-100 Unit Reference | Approx. References per 20 mg Vial |
|---|---|---|---|
| 0.25 mg / 250 mcg | 0.0125 mL | 1.25 units | 80 |
| 0.5 mg / 500 mcg | 0.025 mL | 2.5 units | 40 |
| 1 mg / 1000 mcg | 0.05 mL | 5 units | 20 |
| 2 mg / 2000 mcg | 0.10 mL | 10 units | 10 |
| 5 mg / 5000 mcg | 0.25 mL | 25 units | 4 |
| 10 mg / 10000 mcg | 0.50 mL | 50 units | 2 |
| 20 mg / 20000 mcg | 1.00 mL | 100 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Conversion Reference | Calculation reference only | 0.25 mg reference amount | 1.25 units / 0.0125 mL |
| Low Conversion Reference | Calculation reference only | 0.5 mg reference amount | 2.5 units / 0.025 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 5 units / 0.05 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 2 mg reference amount | 10 units / 0.10 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 25 units / 0.25 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 50 units / 0.50 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 100 units / 1.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Neurotrophic Marker Window | 24–72 hours | May be used for NGF-marker, BDNF-marker, Trk receptor marker, synaptic-marker, neuroprotection-marker, oxidative-stress marker, or cellular-response documentation depending on the model. |
| Acute Neural Observation Window | Single session to several days | Used for early response tracking, neuroprotective-marker comparison, inflammatory-marker observation, or short-term pathway documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for short-duration controlled observation involving neuronal-survival markers, synaptic markers, neurotrophin-system markers, or cellular-stress endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–12 weeks | Used when longer documentation is needed for cognition-marker trends, neurodegenerative-model endpoints, injury-repair markers, synaptic-marker tracking, or follow-up marker documentation. |
| Follow-Up / Washout | 2–8 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Cerebrolysin is treated here as a total 20 mg reference-material amount reconstituted with 1.0 mL bacteriostatic water, creating a 20 mg/mL concentration. Cerebrolysin is commonly discussed in peptide-mixture, neurotrophic-like, NGF / BDNF, Trk receptor, neuroprotection, synaptic-marker, cognition, aging, spinal-cord injury, traumatic brain injury, ischemia-model, and neurodegenerative-model research contexts. Because Cerebrolysin is a mixture-based preparation rather than a single defined peptide sequence, component-level peptide amounts, potency units, and product-specific equivalencies should be verified against the COA, batch record, formula record, or supplier documentation when available. Published study references, clinical-study references, product-format references, and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Cerebrolysin is commonly discussed in research involving neurorecovery, neuroprotection, stroke recovery context, traumatic brain injury models, dementia-related cognitive research, synaptic plasticity, and neurotrophic-like signaling.
Complex Mixture Limitation
Cerebrolysin is not a single defined peptide. Research interpretation depends on product standardization, porcine source material, peptide/amino-acid composition, storage, route, study design, and quality documentation.
Safety Considerations
Research discussion should account for hypersensitivity risk, neurological contraindication context, renal-impairment context, sterility, injection/infusion handling, product authenticity, storage conditions, and qualified professional oversight.
Regulatory Restriction
Not FDA-approved for sale or distribution in the United States. Not for unsupervised use. Not intended to diagnose, treat, cure, or prevent disease when discussed on a research-reference website.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.